Last reviewed · How we verify
NCT04457648
Manuka Honey Eye Drops VS Conventional Treatment of Meibomian Gland Dysfunction Related Dry Eye Disease
Phase 4 trial testing manuka honey 16% eye drops ( Optimel ) in Meibomian Gland Dysfunction in 59 participants. Completed in 1 June 2020.
1 June 2020
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 59 |
| Start date | 1 June 2018 |
| Primary completion | 1 June 2020 |
| Estimated completion | 1 June 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- manuka honey 16% eye drops ( Optimel )
- systane eye drops
Conditions studied
- Meibomian Gland Dysfunction — all drugs for Meibomian Gland Dysfunction →
Sponsor
Chinese University of Hong Kong
Who can join
18 and older, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assessor-masked (Single blind, randomized controlled trial comparing the conventional treatment group to an interventional group using 16% Manuka Honey topical eye drops.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Randomised assessor<b>-</b>masked trial evaluating topical manuka honey (Optimel) in treatment of meibomian gland dysfunction.
Li AL, Li SL, Kam KW, Young AL. · · 2022 · cited 11× · PMID 33419788 · DOI 10.1136/bjophthalmol-2020-317506
Verify or expand the search:
- PubMed search for NCT04457648
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meibomian Gland Dysfunction
Currently open trials in the same condition.
- NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
- NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
- NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
- NCT03652337 — Meibomian Gland Dysfunction Management · NA · active not recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04457648 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 7 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04457648.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing